Abstract:One of the cost-effective alternative methods to find new inhibitors has been the repositioning approach of existing drugs. The advantage of computational drug repositioning method is saving time and cost to remove the pre-clinical step and accelerate the drug discovery process. Hence, an ensemble computational-experimental approach, consisting of three steps, a machine learning model, simulation of drug-target interaction and experimental characterization, was developed. The machine learning type used here was a different tree classification method, which is one of the best randomize machine learning model to identify potential inhibitors from weak inhibitors. This model was trained more than one-hundred times, and forty top trained models were extracted for the drug repositioning step. The machine learning step aimed to discover the approved drugs with the highest possible success rate in the experimental step. Therefore, among all the identified molecules with more than 0.9 probability in more than 70% of the models, nine compounds, were selected. Besides, out of the nine chosen drugs, seven compounds have been confirmed to inhibit EGF in the published articles since 2019. Hence, two identified compounds, in addition to gefitinib, as a positive control, five weak-inhibitors and one neutral, were considered via molecular docking study. Finally, the eight proposed drugs, including gefitinib, were investigated using MTT assay and In-Cell ELISA to characterize the drugs' effect on A431 cell growth and EGF-signaling. From our experiments, we could conclude that salicylic acid and piperazine could play an EGF-inhibitor role like gefitinib.

Identification of New Peptide Ligands for Epidermal Growth Factor Receptor Using Phage Display and Computationally Modeling their Mode of Binding

Identification and Characterization of a Novel Peptide Ligand of Epidermal Growth Factor Receptor for Targeted Delivery of Therapeutics.

Selection of Peptide Ligands Binding to Fibroblast Growth Factor from A Phage Peptide Library

Selection of Peptide Ligands That Bind to Acid Fibroblast Growth Factor

Screening and Identification of Small Peptides Targeting Fibroblast Growth Factor Receptor2 Using a Phage Display Peptide Library

Novel Peptide Ligand Directs Liposomes Toward Egf-R High-Expressing Cancer Cells in Vitro and in Vivo

In silico Identification of Peptide as Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Lung Cancer Treatment

Phage-Displayed Peptide of Keratinocyte Growth Factor and Its Biological Effects on Epidermal Cells

Analysis of Peptide Ligand Binding to FGFR1

Selection of Peptide Ligands Binding to Fibroblast Growth Factor Receptor 1.

Identification of a novel peptide that blocks basic fibroblast growth factor-mediated cell proliferation.

Identification of a Novel Afgf-Binding Peptide with Anti-Tumor Effect on Breast Cancer from Phage Display Library

Identification of a novel peptide ligand for the cancer-specific receptor mutation EGFRvIII using high-throughput sequencing of phage-selected peptides

Keratinocyte Growth Factor Phage Model Peptides Can Promote Epidermal Cell Proliferation Without Tumorigenic Effect.

Design, Synthesis, Anti-Tumor Activity, and Molecular Modeling of Quinazoline and Pyrido[2,3-D]Pyrimidine Derivatives Targeting Epidermal Growth Factor Receptor

Functional evaluation of fluorescein-labeled derivatives of a peptide inhibitor of the EGF receptor dimerization

A novel small molecule ligand for epidermal growth factor receptor targeting

Phage Display Screening Against A Set of Targets to Establish Peptide-Based Sugar Mimetics and Molecular Docking to Predict Binding Site

Selection of Bfgf Mimic Peptide by Phage Display

Identification of new potential candidates to inhibit EGF via machine learning algorithm

Proximity extracellular protein-protein interaction analysis of EGFR using AirID-conjugated fragment of antigen binding